HMS Networks AB’s Acquisition of Red Lion Controls
December 12, 2023
On December 11, 2023, HMS Networks AB (“HMS”), a global provider of industrial information and communication technology, announced it has entered into a binding agreement with Spectris Group Holdings Limited to acquire the Red Lion Controls business, a U.S.-based provider of industrial automation solutions, through the acquisition of 100 percent of the shares in Red Lion Controls Inc. and Red Lion Europe GmbH as well as certain assets in other jurisdictions, for a cash consideration of $345 million. Cravath is representing HMS as special U.S. counsel in connection with the transaction.
The Cravath team includes associate Edward O. Minturn on M&A matters; partner Noah Joshua Phillips and of counsel Jesse M. Weiss on antitrust matters; and of counsel Benjamin G. Joseloff on CFIUS matters. Habib-Emmanuel Abraham also worked on antitrust matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 2005, Stanford Law SchoolWinner, 2005 Marion Rice Kirkwood Moot Court
-
A.B., 2000, Dartmouth CollegePhi Beta Kappa, magna cum laude
- New York
- District of Columbia
Education
Admitted In
- Photo
-
-
J.D., 2008, Georgetown University Law Centermagna cum laude
-
B.A., 2003, University of Maryland
- New York
Education
Admitted In
- Photo
-
-
J.D., 2008, Stanford Law SchoolPro Bono Distinction
-
B.A., 2004, New York UniversityPhi Beta Kappa, summa cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2016, New York University School of Law
-
B.A., 2013, Duke University
- New York
Education
Admitted In
Related News
Deals & Cases
January 13, 2025
Johnson & Johnson’s $14.6 Billion Acquisition of Intra‑Cellular Therapies, Inc.
On January 13, 2025, Johnson & Johnson and Intra‑Cellular Therapies, Inc. announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra‑Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132 per share in cash for a total equity value of approximately $14.6 billion. Cravath is representing Johnson & Johnson in connection with the transaction.
Deals & Cases
October 04, 2024
DRI Healthcare Trust’s Acquisition of Payment Streams Based on the Cas9 Gene‑Editing Technology for CASGEVY®
On October 3, 2024, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, announced that one of its wholly owned subsidiaries acquired a portion of Editas Medicine, Inc.'s payment rights under a non‑exclusive license of Editas' Cas9 gene‑editing technology for CASGEVY®, the only approved gene‑edited cell therapy for sickle cell disease and transfusion‑dependent beta thalassemia, for an upfront purchase price of $57 million. The transaction entitles DRI Healthcare to specific payments based on a sublicensing agreement between Editas and Vertex Pharmaceuticals Incorporated. The payments include a share of the annual license fees that Vertex pays to Editas, which can range from $5 million to $40 million, including certain sales‑based annual license fee increases, and a portion of a $50 million contingent payment to which Editas is eligible under the Vertex sublicensing agreement. Cravath is representing DRI Healthcare in connection with the transaction.
Deals & Cases
September 05, 2024
Frontier’s $20 Billion Acquisition by Verizon
On September 5, 2024, Verizon Communications Inc. and Frontier Communications Parent, Inc. (“Frontier”), the largest pure‑play fiber provider in the U.S., announced they have entered into a definitive agreement for Verizon to acquire Frontier in an all‑cash transaction valued at $20 billion. Cravath is representing Frontier in connection with the transaction.
Deals & Cases
May 07, 2024
Ashland’s Sale of its Nutraceuticals Business to Turnspire Capital Partners
On May 7, 2024, Ashland Inc. (“Ashland”), a global additives and specialty ingredients company, announced that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. Cravath is representing Ashland in connection with the transaction.
